Quadruplet regimens for patients with transplant-ineligible multiple myeloma

Quadruplets in Newly Diagnosed Transplant-Ineligible MyelomaПодробнее

New approaches to treating transplant-ineligible multiple myeloma: triplets and quadrupletsПодробнее

Advancements in quadruplet regimens for the treatment of multiple myelomaПодробнее

Integrating Quadruplet Regimens in Newly Diagnosed Multiple MyelomaПодробнее

Quadruplets vs triplets in newly diagnosed myeloma: is more better?Подробнее

Episode 2 - Integrating Quadruplet Regimens in Newly Diagnosed Multiple Myeloma: Patient Focused ...Подробнее

Isatuximab + Len/Dex/Bortezomib vs IsaRd in Newly Diagnosed Transplant Ineligible Multiple MyelomaПодробнее

Role of 4-Drug Regimens in Treatment of Multiple MyelomaПодробнее

Individualizing treatment in transplant-eligible & transplant-ineligible NDMMПодробнее

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

Best Treatment Options for Transplant Ineligible Myeloma Patients: Doublets-Triplets?Подробнее

Quadruplet regimens and antibodies for newly diagnosed multiple myelomaПодробнее

Quadruplet induction therapy as a new standard of care in multiple myelomaПодробнее

Results of the Myeloma XI study, a quadruplet regimen for transplant eligible patientsПодробнее